Marinus Pharmaceuticals (MRNS)

Sunday

2:33 PM

ThesisRecent positive clinical trial results and potential partnership opportunities are shifting sentiment towards a more favorable outlook for Marinus Pharmaceuticals.

Revenue Outlook

Metric	FY2023	FY2024E	FY2025E
Revenue	$31M	$35M	$55M
Rev. Growth	+21.6%	+12.5%	+58.9%
EPS	$-2.63	$-2.06	$-0.50
EPS Growth	-416%	+21.5%	+75.9%
P/E	—	—	—

★ Analysts see FY2025 revenue reaching $55M — +58.9% growth in a single year.

The Bull Case for Growth

01Recent clinical trial data showed a 45% reduction in seizure frequency for patients treated with ZTALMY, exceeding market expectations.
02The company is in discussions for a potential partnership with a major pharmaceutical firm to co-develop new indications for ZTALMY.
03ZALMY's market penetration in the CDKL5 deficiency disorder segment has reached 30%, indicating strong demand.
04Advancements in neurotherapeutics
05Growing focus on personalized medicine
06Regulatory approvals for new indications of ZTALMY
07Clinical trial results for pipeline candidates
08Market adoption rates of ZTALMY

FY2023 Snapshot

Revenue: $31M
Rev. Growth: +21.6%
Gross Margin: 93.8%
Op. Margin: -424%
Net Margin: -456%
Net Income: $-141M
NI Growth: -614%
EPS: $-2.63
1Y Return: -60.7%

My Notes

"The recent data reinforces our belief in ZTALMY's potential to transform the treatment landscape for epilepsy."
Moat: Marinus has a strong competitive position due to its unique product offering and high gross margins.
growth - Investors are likely attracted to the potential for rapid revenue growth from innovative therapies.
Moderate - Rising interest rates could increase the cost of capital for financing R&D activities, potentially impacting growth initiatives.
Watch on earnings: Sales growth of ZTALMY, Clinical trial success rates, Regulatory approval timelines.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $35M to $55M as recent clinical trial data showed a 45% reduction in seizure frequency for patients treated with ztalmy.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.